Krebs Biochemicals & Industries Ltd , a prominent player in the biochemical industry, has announced significant changes in its leadership and released its financial results for the first quarter. The company's board meeting on August 7 resulted in several key decisions that are set to shape its future direction.

Leadership Transition

The most notable development is the appointment of Manish Kumar Jain as the new Managing Director and CEO of Krebs Biochemicals. Jain, a Chartered Accountant with over 25 years of experience in Strategic Planning, Finance, and Business Development, has been appointed for a five-year term, effective August 7, subject to shareholder approval at the upcoming 33rd Annual General Meeting.

Jain's appointment comes in the wake of Jitendra Shah's resignation from the position of Managing Director and CEO. Shah stepped down citing personal reasons, with his resignation taking effect from the close of business hours on August 7.

Board Committee Restructuring

In light of these changes, Krebs Biochemicals has also announced the reconstitution of its Audit Committee and Stakeholder Relationship Committee, effective August 8. Both committees will now include the newly appointed Managing Director, Manish Kumar Jain, alongside existing independent directors.

The revised Audit Committee structure is as follows:

The reconstituted Stakeholder Relationship Committee comprises:

Q1 Financial Results

During the board meeting, the company also approved its unaudited financial results for the first quarter ended June 30. These results have been subject to a limited review by the company's auditors.

Regulatory Compliance

Krebs Biochemicals has emphasized its commitment to regulatory compliance, stating that these announcements are in line with Regulations 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015.

The company's board meeting, which commenced at 12:00 noon, concluded at 02:05 p.m. on August 7. These developments mark a significant phase in Krebs Biochemicals' corporate journey, potentially setting the stage for new strategies and growth initiatives under the new leadership.

Krebs Biochemicals & Industries , a prominent player in the biochemical industry, has unveiled its unaudited financial results for the first quarter ended June 30, 2025, alongside significant changes in its leadership structure.

Leadership Transition

The company has announced a major leadership change with the appointment of Manish Kumar Jain as the new Managing Director & CEO. Jain, a Chartered Accountant with over 25 years of experience in Strategic Planning, Finance, and Business Development, will take the helm effective August 7, 2025. His appointment is subject to shareholder approval at the upcoming 33rd Annual General Meeting.

Jain's term as Managing Director & CEO is set for five years, extending until August 6, 2028. He will also serve as an Additional Director on the company's board. This appointment comes as Jitendra Shah steps down from his role as Managing Director & CEO, citing personal reasons. Shah's resignation will take effect from the close of business hours on August 7, 2025.

Board Committee Restructuring

In light of these changes, Krebs Biochemicals has also announced a restructuring of its board committees, effective August 8, 2025. The reconstituted committees are as follows:

Audit Committee

• Chairman: P M Kathariya (Independent Director)
• Members:
  • Dipti Shah (Independent Director)
  • Satya Prakash Chigurupati (Independent Director)
  • Sumanth Karlapudi (Independent Director)
  • Manish Kumar Jain (Managing Director & CEO)

Stakeholder Relationship Committee

• Chairman: Sumanth Karlapudi (Independent Director)
• Members:
  • Dipti Shah (Independent Director)
  • Satya Prakash Chigurupati (Independent Director)
  • P M Kathariya (Independent Director)
  • Manish Kumar Jain (Managing Director & CEO)

Q1 Financial Results

The Board of Directors, in their meeting on August 7, 2025, approved the unaudited financial results for the first quarter ended June 30, 2025. While specific financial figures were not disclosed in the announcement, the company confirmed that these results have undergone a limited review by the company's auditors.

Krebs Biochemicals & Industries continues to demonstrate its commitment to transparency and corporate governance through these timely disclosures and leadership transitions. As the company moves forward under new leadership, stakeholders will be keenly watching how these changes impact the company's strategic direction and financial performance in the coming quarters.

The company's shares are listed on both the BSE and the National Stock Exchange of India.